Your browser doesn't support javascript.
loading
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.
Cirkel, G A; Weeber, F; Bins, S; Gadellaa-van Hooijdonk, C G M; van Werkhoven, E; Willems, S M; van Stralen, M; Veldhuis, W B; Ubink, I; Steeghs, N; de Jonge, M J; Langenberg, M H G; Schellens, J H M; Sleijfer, S; Lolkema, M P; Voest, E E.
Afiliación
  • Cirkel GA; Center for Personalized Cancer Treatment (CPCT) Department of Medical Oncology, UMC Utrecht Cancer Center, Utrecht.
  • Weeber F; Center for Personalized Cancer Treatment (CPCT) Department of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam.
  • Bins S; Center for Personalized Cancer Treatment (CPCT) Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam.
  • Gadellaa-van Hooijdonk CG; Center for Personalized Cancer Treatment (CPCT) Department of Radiotherapy, University Medical Center Utrecht, Utrecht.
  • van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam.
  • Willems SM; Center for Personalized Cancer Treatment (CPCT) Department of Pathology, University Medical Center Utrecht, Utrecht.
  • van Stralen M; Image Sciences Institute.
  • Veldhuis WB; Department of Radiology and Nuclear Medicine.
  • Ubink I; Department of Surgery, University Medical Center Utrecht, Utrecht.
  • Steeghs N; Center for Personalized Cancer Treatment (CPCT) Department of Medical Oncology Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam.
  • de Jonge MJ; Center for Personalized Cancer Treatment (CPCT) Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam.
  • Langenberg MH; Center for Personalized Cancer Treatment (CPCT) Department of Medical Oncology, UMC Utrecht Cancer Center, Utrecht.
  • Schellens JH; Center for Personalized Cancer Treatment (CPCT) Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam Department of Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Sleijfer S; Center for Personalized Cancer Treatment (CPCT) Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam.
  • Lolkema MP; Center for Personalized Cancer Treatment (CPCT) Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam.
  • Voest EE; Center for Personalized Cancer Treatment (CPCT) Department of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam e.voest@nki.nl.
Ann Oncol ; 27(8): 1638-43, 2016 08.
Article en En | MEDLINE | ID: mdl-27234642
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Molecular Dirigida / Criterios de Evaluación de Respuesta en Tumores Sólidos / Everolimus / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Molecular Dirigida / Criterios de Evaluación de Respuesta en Tumores Sólidos / Everolimus / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article Pais de publicación: Reino Unido